


Iroxanadine

Chemical Properties

CAS No. :	203805-20-3
Formula:	C ₁₄ H ₂₀ N ₄ O
Molecular Weight:	260.33
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Iroxanadine (BRX-005) is a Novel small molecule MAPK p38 inhibitor that induces phosphorylation of p38 SAPK and induces concentration-dependent relaxation in guinea pig pulmonary artery preparations precontracted with phenylephrine.13480-84-5
Targets(IC50)	HSP,p38 MAPK
In vivo	Iroxanadine improves the survival of vascular endothelial cells (ECs) following ischemia/reperfusion stress. ECs cultured from human umbilical veins were exposed to hypoxia/reoxygenation to mimic ischemia/reperfusion. Caspase activation and apoptosis were monitored in the reoxygenated cells. The addition of Iroxanadine (0.1-1 μM) to the culture medium prior to hypoxia or at the start of reoxygenation significantly reduced the caspase-dependent apoptosis.[1]

Solubility Information

Solubility	DMSO: 45 mg/mL (172.86 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--------------------------------------------------------------------------------------------------------------------------

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.8413 mL	19.2064 mL	38.4128 mL
5 mM	0.7683 mL	3.8413 mL	7.6826 mL
10 mM	0.3841 mL	1.9206 mL	3.8413 mL
50 mM	0.0768 mL	0.3841 mL	0.7683 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kabakov AE, et al. Pharmacological attenuation of apoptosis in reoxygenated endothelial cells. *Cell Mol Life Sci.* 2004;61(24):3076-3086.

Denes L, et al. Reverse regulation of endothelial cells and myointimal hyperplasia on cell proliferation by a heatshock protein-coinducer after hypoxia. *Stroke.* 2008;39(3):1022-1024.

Denes L, Entz L, Jancsik V. Restenosis and therapy. *Int J Vasc Med.* 2012;2012:406236. doi: 10.1155/2012/406236. PubMed PMID: 22489270; PubMed Central PMCID: PMC3303576.

Dénes L, Jednákovits A, Hargitai J, Péntzes Z, Balla A, Tálosi L, Krajcsi P, Csermely P. Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. *Br J Pharmacol.* 2002 Jun;136(4):597-603.

PubMed PMID: 12055138; PubMed Central PMCID: PMC1573374.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481